Braveheart Bio (NASDAQ:BRVE) Director Orbimed Advisors Llc Acquires 1,940,000 Shares

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Orbimed Advisors Llc acquired 1,940,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the acquisition, the director directly owned 11,901,826 shares of the company’s stock, valued at $214,232,868. The trade was a 19.47% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Braveheart Bio Stock Performance

NASDAQ:BRVE traded down $2.52 on Tuesday, reaching $25.01. The company’s stock had a trading volume of 724,651 shares, compared to its average volume of 569,084. Braveheart Bio, Inc. has a 12-month low of $24.61 and a 12-month high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.